Moreover, IRAP is inhibited by angiotensin IV (AngIV), hence IRAP was recognized as a potential target for the treatment of cognitive disorders during the last decade (Albiston et al., 2001; Lew et al., 2003; Albiston et al., 2008; Albiston et al., 2011; Andersson and Hallberg, 2012). Here, LNPEP is linked to cognitive disorder.